The European Union has approved a new HIV treatment that combines the use of Vocabria (cabotegravir injection and tablets) and Janssen Pharmaceutical’s Rekambys (rilpivirine injection and Eudurant (rilpivirine tablets).
Both ViiV Healthcare and The Janssen Pharmaceutical Companies of Johnson & Johnson made the announcement on 21 December.
This monumental step will allow people living with HIV in the EU a more efficient treatment. With these new drugs, the need to take oral tablets daily will be nixed and the days of treatment will only amount to 12 or 6 days.
The new treatment was found effective through a study taken by ViiV Healthcare and Positive Perspectives Wave 2. Dr Antonio Antela from the University Hospital in Santiago de